CMS Modified NCD 152 for Prostate Specific Antigen Testing — What Billing Teams Need to Know in 2026
TL;DR: The Centers for Medicare & Medicaid Services modified NCD 152, the National Coverage Determination governing Medicare PSA testing, effective March 7, 2026. Here's what changes for billing teams.
CMS PSA testing coverage policy under NCD 152 in the Medicare system has been updated. This modification clarifies medical necessity criteria, testing frequency limits, and the clinical contexts where PSA is — and isn't — a covered benefit. The policy does not list specific CPT or HCPCS codes in this version; your billing team should confirm applicable codes through the quarterly Covered Code Lists linked in the CMS policy.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Prostate Specific Antigen — NCD 152 |
| Policy Code | NCD 152 in the Medicare system |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Urology, Oncology, Primary Care, Laboratory |
| Key Action | Audit PSA claim frequency and diagnosis coding against updated medical necessity criteria before billing for the March 7, 2026 effective date |
CMS PSA Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 152 is the National Coverage Determination governing Medicare coverage of Prostate Specific Antigen testing. The updated coverage policy spells out three distinct clinical contexts where PSA testing qualifies as medically necessary. Know which bucket your patient falls into before the claim leaves your system.
Context 1: Lower Urinary Tract Signs and Symptoms
PSA is covered when a man presents with lower urinary tract symptoms — hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia, or incontinence. It's also covered when the prostate gland is palpably abnormal on physician exam, or when other lab or imaging studies suggest a malignant prostate disorder.
For these patients, the frequency limit is strict: once per year, unless there is a documented change in the patient's medical condition. That's not a soft guideline. CMS means it, and a claim for a second PSA in the same year without a documented change in condition is a denial waiting to happen.
Context 2: Established Prostate Cancer Diagnosis
Once a prostate cancer diagnosis is on the chart, PSA becomes a monitoring tool. The coverage policy supports PSA use as a marker to follow tumor progress, detect metastatic disease, and identify persistent disease in patients who may need additional treatment. Frequency restrictions are less rigid here, but medical necessity documentation still needs to connect the test to active monitoring or a clinical decision point.
Context 3: Post-Treatment Monitoring
This is where PSA reimbursement matters most for oncology and urology billing teams. Three to six months after radical prostatectomy, PSA provides a sensitive indicator of persistent disease. At six months following antiandrogen therapy, PSA can distinguish patients with favorable response from those with limited response.
These are specific, time-anchored clinical windows. Document them precisely. "Post-prostatectomy monitoring" on a claim is vague. "Three months post-radical prostatectomy, PSA ordered to assess for persistent disease" is defensible medical necessity language.
Prior Authorization
NCD 152 does not explicitly require prior authorization for PSA testing. However, your Medicare Administrative Contractor may apply local coverage determination rules that add criteria on top of the national policy. Check with your MAC before assuming the NCD is the final word.
CMS PSA Testing Exclusions and Non-Covered Indications
The updated NCD 152 coverage policy is specific about one scenario: in situ carcinoma.
For patients with an in situ carcinoma diagnosis, PSA testing is not reasonable or medically necessary more than once — unless the first result is abnormal. If the result is abnormal, the test may be repeated one time. That's it. One initial test, one repeat if abnormal.
This is a hard limit. It's narrow in scope, but it's the kind of limitation that generates claim denials when billing teams aren't paying attention to diagnosis codes. If your team routinely bills PSA for patients with in situ carcinoma, audit those claims now. A pattern of over-frequency here will catch the attention of a MAC reviewer.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Lower urinary tract signs/symptoms (hematuria, slow stream, hesitancy, urgency, frequency, nocturia, incontinence) | Covered | See CMS Covered Code Lists | Once per year; more frequent only with documented change in medical condition |
| Palpably abnormal prostate on physician exam | Covered | See CMS Covered Code Lists | Part of diagnostic workup; document exam findings |
| Abnormal lab or imaging suggesting malignant prostate disorder | Covered | See CMS Covered Code Lists | Must document the triggering lab or imaging finding |
| Monitoring established prostate cancer diagnosis | Covered | See CMS Covered Code Lists | Includes detecting metastatic or persistent disease |
| Post-radical prostatectomy monitoring (3–6 months) | Covered | See CMS Covered Code Lists | Document time since surgery and clinical rationale |
| Post-antiandrogen therapy monitoring (6 months) | Covered | See CMS Covered Code Lists | Document therapy start date and monitoring rationale |
| Differential diagnosis of undiagnosed disseminated metastatic disease | Covered | See CMS Covered Code Lists | Clinical context must be documented in the record |
| In situ carcinoma — initial test | Covered | See CMS Covered Code Lists | One test only, unless result is abnormal |
| In situ carcinoma — repeat test after abnormal result | Covered (once) | See CMS Covered Code Lists | Maximum one repeat; no further testing covered |
| In situ carcinoma — routine repeated testing (no abnormal result) | Not Covered | See CMS Covered Code Lists | Exceeds frequency limit under NCD 152 |
| Annual repeat PSA without documented change in condition (symptomatic patients) | Not Covered | See CMS Covered Code Lists | Frequency limit applies; requires documented change in condition for additional testing |
CMS PSA Billing Guidelines and Action Items 2026
The real issue with NCD 152 is documentation. CMS isn't saying PSA is hard to get covered — it's saying you have to earn it with the right diagnosis coding and clinical documentation. Here's what your billing team and clinical staff need to do before and after the March 7, 2026 effective date.
| # | Action Item |
|---|---|
| 1 | Pull your PSA claim frequency report now. Run a report for all PSA claims billed in 2025 and 2026 to date. Flag any patients who received more than one test in a 12-month period. For each flagged claim, verify the medical record documents a change in medical condition that justified the additional test. Fix before March 7 if you can. |
| 2 | Audit diagnosis codes on in situ carcinoma patients. Pull all PSA claims where the primary or secondary diagnosis is in situ carcinoma. Confirm each patient had only one test — or one test plus one repeat following an abnormal result. Any claim outside that pattern is at risk. Talk to your compliance officer if you find a pattern of excess billing in this population. |
| 3 | Standardize documentation language for post-treatment PSA. Work with your urologists and oncologists to use time-specific language in orders and notes. "PSA at 3 months post-radical prostatectomy to assess for persistent disease" and "PSA at 6 months post-antiandrogen therapy to evaluate treatment response" are the kinds of phrases that map directly to NCD 152 coverage criteria. Generic orders like "PSA monitoring" don't. |
| 4 | Confirm your applicable CPT codes through the CMS Covered Code Lists. NCD 152 does not list specific CPT or HCPCS codes in this policy version. CMS publishes quarterly Covered Code Lists for NCD 152 with narrative descriptions. Pull the current list and confirm your charge description master reflects the correct codes. If your PSA billing uses a code that dropped off a recent quarterly update, you'll get a denial you won't see coming. |
| 5 | Check your MAC's local coverage determination. NCD 152 sets the national floor. Your Medicare Administrative Contractor may have an LCD that adds frequency limits, diagnosis code requirements, or documentation standards beyond what NCD 152 requires. Contact your MAC or check their website for any active LCDs on PSA testing. Billing to the NCD alone when an LCD adds requirements is a common source of avoidable denials. |
| 6 | Update your ABN process for frequency-limit scenarios. If a patient requests a PSA test that exceeds the once-per-year limit and there's no documented change in medical condition, issue an Advance Beneficiary Notice of Noncoverage before the test is performed. Without an ABN, you can't bill the patient if Medicare denies the claim. This is especially relevant for practices with high-volume preventive care or annual wellness visit workflows where patients ask for PSA testing routinely. |
| 7 | If your practice bills for both diagnostic and screening PSA, keep those workflows separate. The annual screening PSA for Medicare beneficiaries has its own statutory benefit separate from NCD 152. NCD 152 governs diagnostic PSA testing. Mixing them creates coding errors and claim denials. Make sure your front-end staff and coders know which clinical context they're documenting before the claim is built. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for PSA Testing Under NCD 152
The Centers for Medicare & Medicaid Services did not list specific CPT, HCPCS, or ICD-10 codes in this version of NCD 152. This is not unusual for a national coverage determination of this age — CMS maintains the applicable codes in a separate quarterly Covered Code List document linked from the policy.
How to Get the Correct Codes
Go directly to the NCD 152 policy page and scroll to the quarterly Covered Code Lists section. CMS updates these lists every quarter. The narrative descriptions in those lists are the authoritative source for which codes are in and out of coverage at any given time.
Do not rely on codes pulled from older versions of this policy or from third-party sources without cross-checking against the current quarterly list. PSA coding has seen minor updates over the years, and an outdated code on your charge description master is a fast path to a claim denial.
What to Watch For
When you pull the Covered Code List, confirm whether your billing team uses:
- The correct lab test code for PSA (total, free, or complexed — these are distinct analytes and may have distinct codes)
- The correct diagnosis codes for each of the covered clinical contexts in NCD 152
- Any modifier requirements your MAC applies to PSA claims
If you're not sure how this applies to your patient mix — especially if your practice sees a high volume of post-treatment prostate cancer patients — talk to your compliance officer or billing consultant before the March 7, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.